Unknown

Dataset Information

Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth.


ABSTRACT: The major challenges we are facing in cancer therapy with paclitaxel (PTX) are the drug resistance and severe side effects. Massive efforts have been made to overcome these clinical challenges by combining PTX with other drugs. In this study, we reported the first preclinical data that praziquantel (PZQ), an anti-parasite agent, could greatly enhance the anticancer efficacy of PTX in various cancer cell lines, including PTX-resistant cell lines. Based on the combination index value, we demonstrated that PZQ synergistically enhanced PTX-induced cell growth inhibition. The co-treatment of PZQ and PTX also induced significant mitotic arrest and activated the apoptotic cascade. Moreover, PZQ combined with PTX resulted in a more pronounced inhibition of tumor growth compared with either drug al

SUBMITTER: Wu ZH 

PROVIDER: S-EPMC3520897 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature